Document:

EX-4.2

 Exhibit 4.2 

CYTEIR THERAPEUTICS, INC. 

SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

FEBRUARY 5, 2021 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
	 1.
	  	Definitions	  	 	1	
				
		  	1.1	  	“Affiliate”	  	 	1	
				
		  	1.2	  	“Common Stock”	  	 	2	
				
		  	1.3	  	“Damages”	  	 	2	
				
		  	1.4	  	“Default Conversion Shares”	  	 	2	
				
		  	1.5	  	“Derivative Securities”	  	 	2	
				
		  	1.6	  	“Exchange Act”	  	 	2	
				
		  	1.7	  	“Excluded Registration”	  	 	2	
				
		  	1.8	  	“Form S-1”	  	 	2	
				
		  	1.9	  	“Form S-3”	  	 	2	
				
		  	1.10	  	“GAAP”	  	 	2	
				
		  	1.11	  	“Holder”	  	 	2	
				
		  	1.12	  	“Immediate Family Member”	  	 	3	
				
		  	1.13	  	“Initiating Holders”	  	 	3	
				
		  	1.14	  	“IPO”	  	 	3	
				
		  	1.15	  	“Major Investor”	  	 	3	
				
		  	1.16	  	“New Securities”	  	 	3	
				
		  	1.17	  	“Person”	  	 	3	
				
		  	1.18	  	“Preferred Director”	  	 	3	
				
		  	1.19	  	“Preferred Stock”	  	 	3	
				
		  	1.20	  	“RA Capital Fund” means	  	 	3	
				
		  	1.21	  	“Registrable Securities”	  	 	3	
				
		  	1.22	  	“Registrable Securities then outstanding”	  	 	3	
				
		  	1.23	  	“Requisite Directors”	  	 	4	
				
		  	1.24	  	“Restated Certificate”	  	 	4	
				
		  	1.25	  	“Restricted Securities”	  	 	4	
				
		  	1.26	  	“SEC”	  	 	4	
				
		  	1.27	  	“SEC Rule 144”	  	 	4	
				
		  	1.28	  	“SEC Rule 145”	  	 	4	
				
		  	1.29	  	“Securities Act”	  	 	4	
				
		  	1.30	  	“Selling Expenses”	  	 	4	

  
 i 

									
		  	1.31	  	“Series A Preferred Stock”	  	 	4	
				
		  	1.32	  	“Series B Preferred Stock”	  	 	4	
				
		  	1.33	  	“Series C Preferred Stock”	  	 	4	
			
	 2.
	  	Registration Rights	  	 	4	
				
		  	2.1	  	Demand Registration	  	 	4	
				
		  	2.2	  	Company Registration	  	 	6	
				
		  	2.3	  	Underwriting Requirements	  	 	6	
				
		  	2.4	  	Obligations of the Company	  	 	8	
				
		  	2.5	  	Furnish Information	  	 	9	
				
		  	2.6	  	Expenses of Registration	  	 	9	
				
		  	2.7	  	Delay of Registration	  	 	10	
				
		  	2.8	  	Indemnification	  	 	10	
				
		  	2.9	  	Reports Under Exchange Act	  	 	12	
				
		  	2.10	  	Limitations on Subsequent Registration Rights	  	 	12	
				
		  	2.11	  	“Market Stand-off” Agreement	  	 	13	
				
		  	2.12	  	Restrictions on Transfer	  	 	14	
				
		  	2.13	  	Termination of Registration Rights	  	 	15	
			
	 3.
	  	Management and Information Rights	  	 	15	
				
		  	3.1	  	Delivery of Financial Statements	  	 	15	
				
		  	3.2	  	Inspection	  	 	17	
				
		  	3.3	  	Termination of Information	  	 	17	
				
		  	3.4	  	Confidentiality	  	 	17	
				
		  	3.5	  	Critical Technology Matters	  	 	17	
			
	 4.
	  	Rights to Future Stock Issuances	  	 	18	
				
		  	4.1	  	Right of First Offer	  	 	18	
				
		  	4.2	  	Termination	  	 	20	
				
		  	4.3	  	Special Mandatory Conversion	  	 	20	
			
	 5.
	  	Additional Covenants	  	 	20	
				
		  	5.1	  	Insurance	  	 	20	
				
		  	5.2	  	Employee Agreements	  	 	20	
				
		  	5.3	  	Employee Stock	  	 	20	
				
		  	5.4	  	Qualified Small Business Stock	  	 	21	
				
		  	5.5	  	Matters Requiring Investor Director Approval	  	 	21	
				
		  	5.6	  	Board Matters	  	 	22	

  
 -ii- 

									
		  	5.7	  	Successor Indemnification	  	 	22	
				
		  	5.8	  	Indemnification Matters	  	 	23	
				
		  	5.9	  	Termination of Covenants	  	 	23	
				
		  	5.10	  	Right to Conduct Activities	  	 	23	
				
		  	5.11	  	Restrictions on Publicity	  	 	24	
				
		  	5.12	  	Expenses of Counsel	  	 	24	
				
		  	5.13	  	Anti-Harassment Policy	  	 	25	
				
		  	5.14	  	Real Property Holding Corporation	  	 	25	
			
	 6.
	  	Miscellaneous	  	 	25	
				
		  	6.1	  	Successors and Assigns	  	 	25	
				
		  	6.2	  	Governing Law	  	 	26	
				
		  	6.3	  	Counterparts	  	 	26	
				
		  	6.4	  	Titles and Subtitles	  	 	26	
				
		  	6.5	  	Notices	  	 	26	
				
		  	6.6	  	Amendments and Waivers	  	 	27	
				
		  	6.7	  	Severability	  	 	27	
				
		  	6.8	  	Aggregation of Stock	  	 	27	
				
		  	6.9	  	Additional Investors	  	 	27	
				
		  	6.10	  	Entire Agreement	  	 	27	
				
		  	6.11	  	Dispute Resolution	  	 	28	
				
		  	6.12	  	Delays or Omissions	  	 	28	
				
		  	6.13	  	Acknowledgment	  	 	29	
				
		  	6.14	  	Default	  	 	29	
				
		  	6.15	  	Limitation of Liability; Freedom to Operate Affiliates	  	 	29	
				
		  	6.16	  	Further Assurances	  	 	29	

 Schedule A – Schedule of Investors 

Schedule B – Schedule of Key Investors 

  
 -iii- 

 SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

This Second Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of February 5, 2021, by
and among Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the individuals and entities listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto
pursuant to Subsection 6.9 below, the “Investors”). 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Preferred Stock and/or
shares of Common Stock issued upon conversion thereof, and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as of September 27,
2019, between the Company and such Investors (the “Prior Agreement”); 
 WHEREAS, the Existing Investors are holders
of a majority of the Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights
granted to them under the Prior Agreement; and 
 WHEREAS, certain of the Investors are parties to that certain Series C Preferred
Stock Purchase Agreement of even date herewith between the Company and certain of the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the
execution and delivery of this Agreement by such Existing Investors holding at least a majority of the Registrable Securities, and the Company; 

NOW, THEREFORE, the Company and the Investors, including the Existing Investors, each hereby agree that the Prior Agreement
shall be amended and restated, and the parties to this Agreement further agree as follows: 
  

	 	1.	 Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, investment adviser, officer or, director or trustee of such Person, or any venture capital fund, other investment fund
or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. Notwithstanding
the foregoing, where the term “Person” refers to Novo Holdings A/S, in lieu of the foregoing definition, the term “Affiliate” shall mean Novo Ventures (US) Inc., Novo Holdings Equity US Inc., Novo Holdings Equity
Asia Pte. Ltd. (together with Novo Holdings A/S, “Novo”), any partner, executive officer or director of Novo or any venture capital fund or other Person now or hereafter existing formed for the purpose of making investments in other
Persons that is controlled by or under common control with Novo, and for the avoidance of doubt, shall not include any other affiliate of Novo. 

 1.2 “Common Stock” means shares of the Company’s common stock, par
value $0.001 per share. 
 1.3 “Damages” means any loss, damage, claim or liability (joint or several) to which a
party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents
or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Default Conversion Shares” has the meaning ascribed to such term in the Restated Certificate. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in
each case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.7 “Excluded
Registration” means (i) a registration relating-to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a
registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.8 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.9 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.10 “GAAP” means generally accepted
accounting principles in the United States. 
 1.11 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 

  
 -2- 

 1.12 “Immediate Family Member” means a child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, of a natural person
referred to herein. 
 1.13 “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.14 “IPO” means the Company’s first underwritten public offering of its Common Stock under
the Securities Act. 
 1.15 “Major Investor” means (i) any Investor that, individually or together with such
Investor’s Affiliates, holds at least 1,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and (ii) each RA
Capital Fund for so long as such RA Capital Fund holds all of the shares of Series C Preferred Stock purchased by it pursuant to the Purchase Agreement. 

1.16 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.17 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.18 “Preferred Director” means any director of the Company that the holders of record of the Preferred Stock are
entitled to elect pursuant to the Restated Certificate. 
 1.19 “Preferred Stock” means shares of the Company’s Series
A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock. 
 1.20 “RA Capital Fund” means RA Capital
Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. 
 1.21 “Registrable Securities” means (i) the Common Stock
issuable or issued upon conversion of the Preferred Stock that are not Default Conversion Shares; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of
the Company, acquired by the Investors after the date hereof that are not Default Conversion Shares; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a
dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Subsection 2.13 of this Agreement. 
 1.22 “Registrable Securities then outstanding” means the number of shares
determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. 

  
 -3- 

 1.23 “Requisite Directors” means a majority of the Preferred Directors,
provided that if the number of Preferred Directors then in office is two or less, then only the vote of one of the Preferred Directors shall be required. 

1.24 “Restated Certificate” means the Company’s Fifth Amended and Restated Certificate of Incorporation,
as amended and in effect from time to time. 
 1.25 “Restricted Securities” means the securities of the Company required to
bear the legend set forth in Subsection 2.12(b) hereof. 
 1.26 “SEC” means the Securities and Exchange
Commission. 
 1.27 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.28 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.29 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.30 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.31 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001
per share. 
 1.32 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001
per share. 
 1.33 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001
per share. 
  

	 	2.	 Registration Rights. The Company covenants and agrees as follows: 

 

	 	2.1	 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) three (3) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that
the Company file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then outstanding or a lesser percent if the anticipated aggregate offering price,
net of Selling Expenses, would exceed $15 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the
Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Subsection 2.3. 

  
 -4- 

 (b) Form S-3 Demand. If at any time when it
is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $2 million, then the Company
shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any
other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Subsection 2.3.

 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any
twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period other than an Excluded
Registration. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the
effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected three registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the
period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided, that the
Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b)
within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable
registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration
statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d), provided, that if the Initiating
Holders withdraw their request for such registration as a result of a material adverse change to the Company, such withdrawn registration statement shall not be counted as “effected” for purposes of this Subsection
2.1(d). 

  
 -5- 

 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting
Requirements. 
 (a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be
selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned
upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision
of this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders
of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the
Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that
the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

  
 -6- 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or
corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for
the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Subsection
2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of
Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

  
 -7- 

 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to one hundred fifty (150) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 -8- 

 (g) provide a transfer agent and registrar for all Registrable Securities registered
pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $25,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all
selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to
one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material
adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall
not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders (other than fees and disbursements of counsel to any Holder, other than the Selling Holder Counsel, which shall be borne solely by the Holder
engaging such counsel) pro rata on the basis of the number of Registrable Securities registered on their behalf. 

  
 -9- 

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in
settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by
any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
fraud or willful misconduct by such Holder. 

  
 -10- 

 (c) Promptly after receipt by an indemnified party under this Subsection 2.8
of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires,
participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all
other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by
the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Subsection 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case
in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court
of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties
will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and
the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided
further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

  
 -11- 

 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to include securities in any registration other than on a subordinate basis after all Holders have had the opportunity to include in
the registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

  
 -12- 

 2.11 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final
prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, plus an additional eighteen (18) days to the extent necessary as may be
requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in applicable FINRA rules or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to
sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall not
apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the
trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers
and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding stock (after
giving effect to a conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power,
and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with
this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all
Holders subject to such agreements, based on the number of shares subject to such agreements. 

  
 -13- 

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case,
to be bound by the terms of this Agreement 
 (b) Each certificate or instrument representing (i) the Preferred Stock, (ii) the
Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless
otherwise permitted by the provisions of Subsection 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or
following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer, provided that no such notice shall be required in
connection if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company,
shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed
transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not
result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the
Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration; provided that with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Subsection
2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Subsection 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 

  
 -14- 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Subsection 2.1 or Subsection 2.2 shall terminate upon the earlier of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate, where the consideration received by the
Investors is in the form of cash and/or publicly traded securities or where the Investors receive registration rights from the acquiring company or other successor comparable to those set forth in this Section 2; and 

(b) such time after consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale
of all of such Holder’s shares without limitation during a three-month period without registration. 
  

	 	3.	 Management and Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within
one hundred and eighty (180) days after the end of each fiscal year of the Company, (i) an audited balance sheet as of the end of such year, (ii) audited statements of income and of cash flows for such year, and (iii) an audited
statement of stockholders’ equity as of the end of such year, all prepared in accordance with GAAP, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and
as included in the Budget (as defined in Subsection 3.1(d)) for such year; 
 (b) as soon as practicable, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such
fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be
required in accordance with GAAP); 

  
 -15- 

 (c) as soon as practicable, but in any event within 30 days of the end of each month, an
unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such quarters and, promptly after prepared, any other budgets or revised
budgets prepared by the Company; 
 (e) as soon as practicable, but in any event within 30 days after the end of each month, a statement
indicating no change or showing any change in the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable
upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but
reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company
as being true, complete, and correct. 
 (f) such other information relating to the financial condition, business, prospects, or corporate
affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company
reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company) or (ii) the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are
consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules
applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 

  
 -16- 

 3.2 Inspection. The Company shall permit each Major Investor (provided that
the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and
discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated
pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information. The covenants set forth in Subsection 3.1 and Subsection 3.2 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the
closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first; provided, that, with respect to clause (iii), the covenants set forth in Section 3.1 and 3.2
shall only terminate if the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities unless the Major Investors receive financial information from the acquiring company or
other successor to the Company comparable to those set forth in Section 3.1. 
 3.4 Confidentiality. Each
Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the
Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a
result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or
disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its
attorneys, accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable
Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such
Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be
required by law, regulation, rule, court order or subpoena, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

3.5 Critical Technology Matters. 

(a) To the extent (i) any pre-existing products or services provided by the Company are re-categorized by the U.S. government as a critical technology within the meaning of Section 721 of the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the
“DPA”), or would reasonably be considered to constitute the design, fabrication, development, testing, production or manufacture of a critical technology after a re-categorization of selected
technologies by the U.S. government, or (ii) after execution of the Purchase Agreement, the Company engages in any activity that could reasonably be considered to constitute the design, fabrication, development, testing, production or
manufacture of a critical technology within the meaning of the DPA, the Company shall promptly notify the Investors of such change in the categorization of its products or services. 

  
 -17- 

 (b) If and only if (i) the Committee on Foreign Investment in the United States or any
member agency thereof acting in such capacity (“CFIUS”) requests or requires that any Investor or the Company file a notice or declaration with CFIUS pursuant to the DPA with respect to such Investor’s investment in the Company
(the “Covered Transactions”) or (ii) such Investor or the Company reasonably determines that a filing with CFIUS with respect to the Covered Transactions is advisable or required by applicable law, then in either case,
(i) or (ii): (x) the Company and each Investor shall, and shall cause its Affiliates to, cooperate with the other parties hereto and shall promptly file a CFIUS filing in the requested, required or advisable form in accordance with the DPA;
(y) the Company and each Investor shall, and shall cause its Affiliates to, use reasonable best efforts to obtain, as applicable, the CFIUS Satisfied Condition (as defined in the Restated Certificate); and (z) the Company shall provide
notice of clause (i) or (ii) to the Major Investors. For the avoidance of doubt, each such Investor shall have no obligation to accept or take any action, condition or restriction with respect to the Covered Transactions in order to achieve the
CFIUS Satisfied Condition. 
  

	 	4.	 Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if
the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as
it deems appropriate, among (i) itself and (ii) its Affiliates; provided that, each such Affiliate (x) is not a competitor of the Company as reasonably determined by the Board of Directors, unless such party’s purchase of
New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this Agreement and each of the Third Amended and Restated Voting Agreement and Second Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided that, any competitor of the
Company as reasonably determined by the Board of Directors shall not be entitled to any rights as an Investor under Subsections 3.1, 3.2 or 4.1 hereof), and (z) agrees to purchase at least such number of New Securities as
are allocable hereunder to the Investor holding the fewest number of Preferred Stock and any other Derivative Securities. For purposes of this Agreement, neither Celgene Corporation nor its Affiliates are “a competitor of the Company”.

 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention
to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

  
 -18- 

 (b) By notification to the Company within twenty (20) days after the Offer Notice is
given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock that are not Default
Conversion Shares then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by
such Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities and excluding any Default Conversion Shares). At the
expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major
Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the
number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock that are
not Default Conversion Shares issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the
Common Stock, that are not Default Conversion Shares, issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising
Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of forty-five (45) days of the date that the Offer Notice is given and the
date of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities referred to in the
Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection
4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company
does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and
such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1. 

(d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Restated Certificate); and (ii) shares of Common Stock issued in the IPO. 
 (e) Notwithstanding any provision hereof to the contrary,
in lieu of complying with the provisions of this Subsection 4.1, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and
terms of the New Securities. Each Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s
percentage- ownership position, calculated as set forth in Subsection 4.1(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is
given to the Major Investors. 

  
 -19- 

 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and
be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

4.3 Special Mandatory Conversion. For purposes of the Restated Certificate, only those Investors set forth on Schedule B
attached hereto shall constitute “Key Investors” (as defined and used in Article IV of the Restated Certificate). 
  

	 	5.	 Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain Directors and Officers liability insurance
covering the Company’s directors and officers, with a minimum coverage amount of $3 million and on terms and conditions satisfactory to the Board of Directors, including the Requisite Directors, until such time as the Board of Directors
determines that such insurance should be discontinued. In the event the Company merges with another entity and the Company is not the surviving corporation, or transfers all of its assets, proper provisions shall be made so that successors of the
Company assume the Company’s obligations with respect to indemnification of directors. 
 5.2 Employee Agreements. The Company
will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement and
(ii) each Key Employee (as defined in the Purchase Agreement) to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form previously approved by the Board of Directors (a copy of which has been made
available to Investors). In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee,
without the consent of the Requisite Directors. 
 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including
the Requisite Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted
stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty- five percent (25%) of such shares vesting following twelve (12) months of continued employment or
service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision
substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, including the Requisite Directors, the Company shall retain a “right of first refusal” on employee transfers
until the Company’s IPO and shall have the right to repurchase unvested shares at the lesser of cost or fair market value of any unvested shares held by such holder upon termination of employment of a holder of restricted stock. 

  
 -20- 

 5.4 Qualified Small Business Stock. The Company shall use commercially
reasonable efforts to cause the shares of Preferred Stock issued on or before September 27, 2019, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the
“Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors of the
Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any
reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its
option, either (i) deliver to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of
the Code or (ii) deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company
constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. 
 5.5 Matters Requiring Investor
Director Approval. So long as the holders of Preferred Stock are entitled to elect a Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must
include the affirmative vote of the Requisite Directors: 
 (a) form any subsidiary or enter into a joint venture; 

(b) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (c) make, or permit any subsidiary to make, any loan
or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan
approved by the Board of Directors; 
 (d) guarantee or assume, directly or indirectly, or permit any subsidiary to guarantee or assume,
directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(e) make any investment inconsistent with any investment policy approved by the Board of Directors; 

(f) create or authorize the creation of any indebtedness, including without limitation any debt security, if the Company’s aggregate
indebtedness would exceed $500,000 to the extent not already included in a Budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(g) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate”
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by this Agreement, the Purchase Agreement, and transactions resulting in payments to or by
the Company in the form of compensation or benefits in the ordinary course of business; 

  
 -21- 

 (h) hire, fire, or change the compensation of the Chief Executive Officer, President, Chief
Scientific Officer, Chief Medical Officer, or Chief Financial Officer, including approving or modifying any option grants or stock awards; 

(i) change the principal business of the Company, enter new lines of business, or exit the current line of business (provided that a change
in Company’s lead candidate(s) or back-up candidate(s) in connection with oncology-related diseases and indications shall not be deemed to be a change of entering a new line of business or exiting a
current line of business requiring the approval described in this Section 5.5); 
 (j) create or hold capital
stock in any subsidiary that is not a wholly-owned subsidiary or dispose of any subsidiary stock or all or substantially all of any subsidiary assets; 

(k) acquire all of the equity securities of another entity, or all or substantially all of the assets of another entity; 

(l) enter into any corporate strategic relationship involving the payment, contribution or assignment by the Company or to the Company of
assets greater than $250,000; 
 (m) sell, assign, license, pledge, or encumber material technology or intellectual property, other than
licenses granted in the ordinary course of business; and 
 (n) enter into an agreement to do any of the foregoing. 

5.6 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred
(consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Each committee of the Board of Directors shall comprise no fewer than three members. 

5.7 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger or the Company or any subsidiary of the Company sells or otherwise transfers all or substantially all of the assets or intellectual property of the Company,
then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately
before such transaction, whether such obligations are contained in the Company’s Bylaws, the Restated Certificate, or elsewhere, as the case may be. 

  
 -22- 

 5.8 Indemnification Matters. The Company hereby acknowledges that the Preferred
Directors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Preferred Director Indemnitors”). The
Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Preferred Director are primary and any obligation of the Preferred Director Indemnitors to advance expenses or to provide indemnification for
the same expenses or liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred Director and shall be liable for the full amount of all expenses,
judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Restated Certificate or Bylaws of the Company (or any agreement between the Company and
such Preferred Director), without regard to any rights such Preferred Director may have against the Preferred Director Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Preferred Director Indemnitors from any and
all claims against the Preferred Director Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Preferred Director Indemnitors on behalf of
any such Preferred Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect the foregoing and the Preferred Director Indemnitors shall have a right of contribution and/or be
subrogated to the extent of such advancement or payment to all of the rights of recovery of such Preferred Director against the Company. 

5.9 Termination of Covenants. The covenants set forth in this Section 5, except for Subsection 5.7,
shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 
 5.10
Right to Conduct Activities. The Company hereby acknowledges that (a) each of Venrock Associates VII, L.P., Venrock Partners VII, L.P. (collectively, along with their affiliates, “Venrock”), Droia Invest II SCSP
(together with its affiliates, “Droia”), Lightstone Ventures II, L.P., Lightstone Ventures II (A), L.P. (collectively, along with their affiliates, “Lightstone”), Novo (together with their affiliates), RA Capital
Funds (together with their affiliates), Ally Bridge MedAlpha Master Fund L.P. (together with its affiliates, “Ally Bridge”), Janus Henderson Global Life Sciences Fund, Janus Henderson Biotech Innovation Master Fund Limited, Janus
Henderson Capital Funds plc on behalf of its series Janus Henderson Global Life Sciences Fund and Janus Henderson Horizon Fund—Biotechnology Fund (collectively, along with their affiliates, “Janus”), Baker Brothers Life
Sciences, L.P. and 667, L.P. (collectively, along with their affiliates, “Baker Brothers”) and CaaS Opportunity LLC (together with its affiliates, “CaaS”) (“Fund Investors”) are professional
investment funds, and as such invest capital in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted); and (b) Celgene Corporation
(“Celgene”) invests capital in other companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the
extent permitted under applicable law, Fund Investors and Celgene shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by a Fund Investor or Celgene in any entity competitive with the Company, or
(ii) actions taken by any partner, officer or other representative of a Fund Investor or Celgene to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or
otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) a Fund Investor or Celgene from liability associated with the unauthorized disclosure
of the Company’s confidential information obtained pursuant to this Agreement, or any other agreement (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company or
(z) Celgene from a breach of any other agreement with the Company. For the avoidance of doubt, no Fund Investor shall be deemed “a competitor of the Company” for purposes of Subsections 3.1, 3.2 or 4.1. 

  
 -23- 

 5.11 Restrictions on Publicity. The Company shall not use the name of Novo or
its Affiliates, or refer to Novo or its Affiliates, directly or indirectly, in connection with Novo’s or its Affiliates’ relationship, agreements or arrangements with the Company in any advertisement, press release, professional or trade
publication, marketing materials or otherwise to the general public or in any other manner, except (i) as may be required by law, (ii) on a confidential basis to potential financing sources, including lenders, investors, investment bankers
or acquirors but only as to the fact of Novo’s equity investment in the Company and documentation relating thereto, (iii) on a confidential basis to the Company’s lawyers, contractors, accountants and other advisors who have a need to
have access and knowledge of such information, or (iv) with Novo’s, as applicable, prior written consent, which consent may be withheld in its sole discretion; provided that (i) the parties anticipate that there will be a
mutually-agreed press release announcing the closing of the transactions contemplated in the Purchase Agreement and (ii) following the public announcement contemplated in clause (i), the Company may confirm that Novo are investors in the
Company (but not the amount or terms thereof) in a form of disclosure that has been previously approved by Novo, as applicable. 
 5.12
Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Third Amended and Restated Voting Agreement of even date herewith among the Company, the Investors and the other parties named therein), the
reasonable fees and disbursements, not to exceed $30,000 in the aggregate, of one counsel for the Major Investors (“Investor Counsel”) in their capacities as stockholders, shall be borne and paid by the Company. At the outset of
considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information
(including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans)
pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers
to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a
joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and
deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel
to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good
faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 

  
 -24- 

 5.13 Anti-Harassment Policy. The Company shall, within sixty (60) days following
the Closing (as defined in the Purchase Agreement), adopt and thereafter maintain in effect (i) a Code of Conduct governing appropriate workplace behavior and (ii) an Anti-Harassment and Discrimination Policy prohibiting discrimination and
harassment at the Company. Such policy shall be reviewed and approved by the Board of Directors. 
 5.14 Real Property Holding
Corporation. Promptly following (and in any event within ten (10) days after receipt of) written request by an Investor, the Company shall provide such Investor with a written statement informing such Investor whether such Investor’s
interest in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements of Treasury Regulation Section 1.897-2(h)(1) or any
successor regulation, and the Company shall provide timely notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any
successor regulation, that such statement has been made. The Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be regularly traded on an established
securities market or the fact that there is no Preferred Stock then outstanding. 
  

	 	6.	 Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds at least twenty-five percent (25%) of the shares of Registrable Securities held by the Holder at the time Holder first entered in this Agreement (subject to appropriate adjustment for stock splits, stock
dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the
Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including
the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who
is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided
further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any
rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. 

  
 -25- 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the State
of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal
business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B hereto, as applicable, or to the principal office of the Company and to the attention of the Chief Executive Officer, in
the case of the Company, or to such email address, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Marc Rubenstein,
Esq., Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02119-3600; if notice is given to The David and Barbara Roux Trust udt 8/11/99, a copy shall also be given to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, One
Financial Place, Boston, MA 02111, Attn: Michael Fantozzi; if notice is given to Celgene Corporation, a copy shall also be given to Assistant Secretary, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901; if notice is given to Venrock, a copy
shall also be given to Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304, Attn: Steven E. Bochner; if notice is given to Novo, a copy (which shall not constitute notice) shall also be given to Wilson
Sonsini Goodrich & Rosati P.C., 12235 El Camino Real, San Diego, California 92130, Attention: Dan Koeppen, Esq; if notice is given to RA Capital Fund, a copy (which shall not constitute notice) shall also be given to Cooley LLP, 500
Boylston Street, Floor 14, Boston, MA 02116, Attention: Ryan S. Sansom; if notice is given to Janus, a copy (which shall not constitute notice) shall also be given to Stradley Ronon Stevens & Young, LLP, 457 Haddonfield Road, Suite 100,
Cherry Hill, NJ 08002-2223, Attention: Daniel Knox; and if notice is given to Ally Bridge, a copy (which shall not constitute notice) shall also be given to Latham & Watkins, LLP, 200 Clarendon Street, Boston, MA 02116, Attention: Peter
Handrinos. 

  
 -26- 

 6.6 Amendments and Waivers. Any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a
majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after
notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such
party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the
written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular
transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction),
(b) Subsections 3.5, 5.10, 5.11, 6.11, 6.15, this clause (b) of this Subsection 6.6 and the definition of Affiliate as it pertains to Novo may not be amended or terminated and the observance of any term
may not be waived without the written consent of Novo. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any
amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition,
or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
the Company’s Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter
shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to
be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement. This Agreement (including any
Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between
the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

  
 -27- 

 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the Court of Chancery of the State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware (the “Courts”) for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the Courts, and (c) hereby waive, and agree not to assert, by way
of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the Courts, that its property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by the Courts. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 Each party will bear its own costs in respect of any disputes
arising under this Agreement. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter
jurisdiction. 
 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under
this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such
breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 -28- 

 6.13 Acknowledgment. The Company acknowledges that the Investors are in the business
of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company.
Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

6.14 Default. In the event of a Special Mandatory Conversion (as defined in the Restated Certificate) by an Investor, such Investor
shall lose all of its rights under this Agreement with respect to the Default Conversion Shares, except with respect to Sections 5.8 and 5.10. For the avoidance of doubt, each Investor shall remain subject to all of the obligations of
an Investor hereunder, including, without limitation, Sections 2.11, 2.12, and 3.4. 
 6.15 Limitation of Liability;
Freedom to Operate Affiliates. The total liability, in the aggregate, of each of the Investors and its respective Affiliates, officers, directors, employees and agents, for any and all claims, losses, costs or damages, including attorneys’
and accountants’ fees and expenses and costs of any nature whatsoever or claims or expenses resulting from or in any way related to this Agreement from any cause or causes shall be several and not joint with the other Investors and in the case
of each Investor shall not exceed the total purchase price paid to the Company by the Investor for the shares of capital stock of the Company purchased by the Investor. It is intended that this limitation apply to any and all liability or cause of
action however alleged or arising, unless otherwise prohibited by law. Nothing in this Agreement or the Transaction Agreements (as defined in the Purchase Agreement) shall restrict the Investors’ freedom to operate any of its affiliates
(including any such affiliate that is a potential competitor of the Company). 
 6.16 Further Assurances. At any time or from time to
time after the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably
request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder. 

[Remainder of Page Intentionally Left Blank] 

  
 -29- 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	CYTEIR THERAPEUTICS, INC.
		
	By:	 	/s/ Markus Renschler

 
			
	 Name:
	 	 Markus Renschler

	 Title:
	 	 President & Chief Executive Officer

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC
Its General Partner
		
	By:	 	/s/ Rajeev Shah

 
			
	Name:	 	Rajeev Shah

 
			
	Title:	 	Manager

 
			
	Address:	 	RA Capital Management, L.P.
		 	200 Berkeley Street,
		 	 18th Floor

Boston, MA 02116
 Attn: General Counsel

  

			
	RA CAPITAL NEXUS FUND II, L.P.
	
	By: RA Capital Nexus Fund II GP, LLC
Its: General Partner
		
	By:	 	/s/ Rajeev Shah

 
			
	Name:	 	Rajeev Shah

 
			
	Title:	 	Manager

 
			
	Address:	 	RA Capital Management, L.P.
		 	200 Berkeley Street,
		 	 18th Floor

Boston, MA 02116
 Attn: General
Counsel

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

							
		 	 INVESTORS:

		
	JANUS HENDERSON GLOBAL LIFE SCIENCES FUND	 	 JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED

		
	By: Janus Capital Management LLC, its investment advisor	 	By: Janus Capital Management LLC, its investment advisor
				
	By:	 	/s/ Andrew Acker	 	By:	 	/s/ Andrew Acker
	Name:	 	Andrew Acker	 	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory	 	Title:	 	Authorized Signatory

							
	Address:	 	c/o Janus Capital Management LLC	 	Address:	 	c/o Janus Capital Management LLC
		 	151 Detroit Street	 		 	151 Detroit Street
		 	Denver, CO 80206	 		 	Denver, CO 80206
		 	Attn: Andy Acker	 		 	Attn: Andy Acker
		 	Attn: Angela Morton	 		 	Attn: Angela Morton

  

							
	 JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	 	 JANUS HENDERSON HORIZON FUND - BIOTECHNOLOGY FUND

		
	By: Janus Capital Management LLC, its investment advisor	 	By: Janus Capital Management LLC, its investment advisor
				
	By:	 	/s/ Andrew Acker	 	By:	 	/s/ Andrew Acker
	Name:	 	Andrew Acker	 	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory	 	Title:	 	Authorized Signatory

							
	Address:	 	c/o Janus Capital Management LLC	 	Address:	 	c/o Janus Capital Management LLC
		 	151 Detroit Street	 		 	151 Detroit Street
		 	Denver, CO 80206	 		 	Denver, CO 80206
		 	Attn: Andy Acker	 		 	Attn: Andy Acker
		 	Attn: Angela Morton	 		 	Attn: Angela Morton

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	667, L.P.
	
	BY: BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general
partner.
		
	By:	 	/s/ Scott Lessing

 
			
	Name:	 	Scott Lessing
	Title:	 	President
	Address:	 	Baker Bros. Advisors LP
		 	860 Washington St., 3rd Floor
		 	New York, N.Y. 10014

  

			
	BAKER BROTHERS LIFE SCIENCES, L.P.
	
	By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general
partner to Baker Brothers Life Sciences, L.P., and not as the general partner.
		
		 	/s/ Scott Lessing
		 	Name: Scott Lessing
		 	Title: President
		 	 Address: Baker Bros. Advisors LP

860 Washington St., 3rd Floor

New York, N.Y. 10014

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ALLY BRIDGE MEDALPHA MASTER FUND L.P.
	
	By: Ally Bridge Group (NY) LLC, its manager
		
	By:	 	/s/ Anna Yaeger

 
			
	Name:	 	Anna Yaeger
	Title:	 	Portfolio Manager and President
	Address:	 	c/o Ally Bridge Group (NY) LLC
		 	 430 Park Avenue, 12th Floor
 New York, NY
10022

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ACUTA CAPITAL FUND, LP
	
	By: Acuta Capital Partners, LLC
	Its: General Partner
	
	By: /s/ Scott R.
Smith                                        
        
	Name: Scott R. Smith
	Title: Chief Operating Officer
	Address:	 	 1301 Shoreway Road, Suite 350,
 Belmont, CA
94002

  

			
	ACUTA OPPORTUNITY FUND, LP
	
	By: Acuta Capital Partners, LLC
	Its: General Partner
	
	By: /s/ Scott R.
Smith                                        
        
	Name: Scott R. Smith
	Title: Chief Operating Officer
	Address:	 	 1301 Shoreway Road, Suite 350,
 Belmont, CA
94002

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	AVIDITY MASTER FUND LP
	
	By: Avidity Capital Partners Fund (GP) LP,
	its General Partner
	
	By: /s/ Michael
Gregory                                        
    
	Name:   Michael Gregory
	Title:     Director
	Address:	 	 2828 N. Harwood St., Suite 1220
 Dallas, TX
75201

  

			
	AVIDITY CAPITAL FUND II LP
	
	By: Avidity Capital Partners Fund (GP) LP,
	its General Partner
	
	By: /s/ Michael
Gregory                                        
    
	Name:   Michael Gregory
	Title:     Director
	Address:	 	 2828 N. Harwood St., Suite 1220
 Dallas, TX
75201

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	STRENGTH ALLIANCE LIMITED
	c/o Ample Plus Fund Limited Partnership
	
	By: /s/ Chunshan
Tang                                         
       
	Name: Chunshan Tang
	Title: Authorized Signatory
	Address:	 	 One Broadway, 9th Floor

Cambridge, MA 02142

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CAAS OPPORTUNITY LLC
	
	By: /s/ Semi
Gogliormella                                       
     
	Name: Semi Gogliormella
	Title: COO

 
			
	Address:	 	 800 Third Avenue, 26th floor
 New York, New York
10022

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	NOVO HOLDINGS A/S
	
	By: /s/ Scott
Beardsley                                        
        
	Name: Scott Beardsley
	            under specific power of attorney
	Title:    Managing Partner

 
			
	Address:	 	 Novo Holdings A/S
 Tuborg Havnevej 19

DK 2900 Hellerup
 Denmark

  
 SIGNATURE PAGE TO SECOND AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	DROIA INVEST II SCSP
	
	By: DF II GP Sàrl, Its: General Partner

 
			
		
	By:	 	/s/ Janwillem Naesens

 
			
	Name:	 	Janwillem Naesens
		 	(representing Wepaven BV)
	Title:	 	Manager

 
			
	Address:	 	    Boulevard Joseph II 28
		 	    L-1840 Luxembourg

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTORS:

	
	VENROCK ASSOCIATES VII, L.P.
	
	By: Venrock Management VII, LLC
	Its: General Partner
		
	By:	 	/s/ David L. Stepp

 
			
	Name:	 	David L. Stepp

 
			
	Title:	 	Authorized Signatory

 
			
	Address:	 	    3340 Hillview Avenue
		 	    Palo Alto, CA 94304
	
	VENROCK PARTNERS VII, L.P.
	
	By: Venrock Management VII, LLC
	Its: General Partner

 
			
		
	By:	 	/s/ David L. Stepp

 
			
	Name:	 	David L. Stepp

 
			
	Title:	 	Authorized Signatory

 
			
	Address:	 	    3340 Hillview Avenue
		 	    Palo Alto, CA 94304

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	OSAGE UNIVERSITY PARTNERS II, LP
	
	By: Osage University GP II, LLC
	Its: General Partner
		
	By:	 	/s/ William T. Harrington

 
			
	Name:	 	William Harrington

 
			
	Title:	 	Managing Member

 
			
	Address:	 	    50 Monument Rd., Suite 201
		 	    Bala Cynwyd, PA 19004

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LIGHTSTONE VENTURES II, L.P.

 
			
		
	By:	 	/s/ Jean George

 
			
	Name:	 	Jean George

 
			
	Title:	 	General Partner

 
			
	Address:	 	    500 Boylston Street, Suite 1380
		 	    Boston, MA 02116
	
	LIGHTSTONE VENTURES II (A), L.P.

 
			
		
	By:	 	/s/ Jean George

 
			
	Name:	 	Jean George

 
			
	Title:	 	General Partner

 
			
	Address:	 	    500 Boylston Street, Suite 1380
		 	    Boston, MA 02116

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CELGENE CORPORATION
		
	By:	 	/s/ Daniel O’Connell

 
			
	Name:	 	Daniel O’Connell

 
			
	Title:	 	Authorized Signatory

 
			
	Address:	 	    86 Morris Avenue
		 	    Summit, NJ 07901

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	THE JACKSON LABORATORY
		
	By:	 	/s/ Douglas Abbott

 
			
	Name:	 	Douglas Abbott
	Title:	 	CFO

 
			
	Address:	 	    c/o Mary McWade
		 	     Merrill Lynch

    Private Banking & Investment Group

    100 Federal Street, 17th Floor
     MA5-100-17-7

    Boston, MA 02110

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Z INVESTMENTS, LLC
		
	By:	 	/s/ Joseph S Zakrzewski

 
			
	Name:	 	Joseph S Zakrzewski
	Title:	 	Managing Director

 
			
	Address:	 	    [***]
		 	    [***]

 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
	Signature:	 	/s/ Timothy Romberger

 
			
	Name:	 	Timothy Romberger

 
			
	Address:	 	    [***]
		 	    [***]

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

SERIES A INVESTORS 
  

					
	 Name and Address
	  	Number of Shares of
Series A Preferred
Stock Held	 
	 The David and Barbara Roux Trust udt 8/11/99

[***]
	  	 	2,000,000	 
	Celgene Corporation 
86 Morris Avenue 
Summit, NJ 07901	  	 	2,000,000	 
	 Anthony Evnin 
[***]
	  	 	250,000	 
	 Weslie Janeway 
[***]
	  	 	250,000	 
	 Milch Investment Holdings, LLC 
[***]
	  	 	250,000	 
	David Shaw 
c/o Mary McWade 
Merill Lynch 
Private Banking & Investment Group 
100 Federal Street 17th Floor

MA5-100-17-7 
Boston, MA 02110	  	 	250,000	 
	Elmrock Energy Holdings 
c/o Elmrock 
150 East 58th Street 27th Floor 
New York, NY 10155	  	 	250,000	 
	 Mills Family 1 LLC 
[***]
	  	 	75,000	 
	 K&BM LP 
[***]
	  	 	75,000	 

					
	 Krishnan-Shah Family Partners, LP 
[***]
	  	 	100,000	 
	 Geis-Hides Consulting 
[***]
	  	 	83,403	 
	 Timothy Romberger 
[***]
	  	 	69,503	 
	 Robert Barbanell 
[***]
	  	 	32,545	 
	 William Rudolf 
[***]
	  	 	32,545	 
	 Farzad Nazem & Noosheen Hashemi Living Trust Dated 07/10/95 
[***]
	  	 	100,000	 

 SCHEDULE A (cont.) 

SERIES B INVESTORS 
  

					
	 Name and Address
	  	Number of Shares of Series B
Preferred Stock Held	 
	 Venrock Associates VII, L.P.

3340 Hillview Avenue

Palo Alto, CA 94304
	  	 	9,235,000	 
	 Venrock Partners VII, L.P.

3340 Hillview Avenue

Palo Alto, CA 94304
	  	 	765,000	 
	 DROIA Invest II SCSP

Boulevard Joseph II 28

L-1840 Luxembourg
	  	 	10,000,000	 
	 Lightstone Ventures II, L.P.

500 Boylston Street, Suite 1380

Boston, MA 02116
	  	 	7,115,217	 
	 Lightstone Ventures II (A), L.P.

500 Boylston Street, Suite 1380

Boston, MA 02116
	  	 	384,783	 
	 Osage University Partners II, LP

50 Monument Rd., Suite 201

Bala Cynwyd, PA 19004
	  	 	7,592,987	 
	 Celgene Corporation

86 Morris Avenue

Summit, NJ 07901
	  	 	3,957,013	 
	 Anthony Evnin

[***]
	  	 	250,000	 
	 Weslie Janeway

[***]
	  	 	500,000	 
	 Milch Investment Holdings, LLC

[***]
	  	 	500,000	 

					
		
	 Elmrock Energy Holdings, LLC 

c/o Elmrock 

150 East 58th Street, 27th Floor 

New York, NY 10155
	  	 	500,000	 
	 Timothy Romberger

[***]
	  	 	200,000	 
	 Novo Holdings A/S

Tuborg Havnevej 19

DK-2900 Hellerup

Denmark

Attn: Heather Ludvigsen

Email: [***]
  

with a copy (which shall not constitute notice) to:

 
 Novo Ventures (US), Inc.

501 2nd Street, Suite 300

San Francisco, CA 94107

United States

Attention: Junie Lim and Karen Hong

Email: [***] and [***]
	  	 	14,000,000	 
	 Z Investments, LLC

[***]
	  	 	200,000	 

 SCHEDULE A (cont.) 

SERIES C INVESTORS 
  

					
	 Name and Address
	  	Number of Shares of Series C
Preferred Stock Held	 
	 RA Capital Healthcare Fund, L.P.

c/o RA Capital Management, L.P.

200 Berkeley Street

18th Floor

Boston, MA 02116

Attn: General Counsel
	  	 	5,786,611	 
	 RA Capital NEXUS Fund II, L.P.

c/o RA Capital Management, L.P.

200 Berkeley Street

18th Floor

Boston, MA 02116

Attn: General Counsel
	  	 	1,021,167	 
	 Janus Henderson Global Life Sciences Fund

c/o Janus Capital Management LLC

151 Detroit Street

Denver, CO 80206

Attn: Andy Acker [***]

Attn: Angela Morton [***]
	  	 	1,873,655	 
	 Janus Henderson Biotech Innovation Master Fund Limited

c/o Janus Capital Management LLC

151 Detroit Street

Denver, CO 80206

Attn: Andy Acker [***]

Attn: Angela Morton [***]
	  	 	621,760	 
	 Janus Henderson Capital Funds plc on behalf of its series

Janus Henderson Global Life Sciences Fund

c/o Janus Capital Management LLC

151 Detroit Street

Denver, CO 80206

Attn: Andy Acker [***]

Attn: Angela Morton [***]
	  	 	1,521,076	 

					
	 Name and Address
	  	Number of Shares of Series C
Preferred Stock Held	 
	 Janus Henderson Horizon Fund – Biotechnology Fund

c/o Janus Capital Management LLC

151 Detroit Street

Denver, CO 80206

Attn: Andy Acker [***]

Attn: Angela Morton [***]
	  	 	68,176	 
	 667, L.P.

c/o Baker Bros. Advisors L.P.

860 Washington Street

3rd Floor

New York, NY 10014
	  	 	120,790	 
	 Baker Brothers Life Sciences, L.P.

c/o Baker Bros. Advisors L.P.

860 Washington Street

3rd Floor

New York, NY 10014
	  	 	1,513,076	 
	 Ally Bridge MedAlpha Master Fund L.P.

430 Park Avenue

12th Floor

New York, NY 10022
	  	 	1,089,244	 
	 Acuta Capital Fund, LP

1301 Shoreway Road, Suite 350

Belmont, CA 94002

Attn: Scott Smith, Chief Operating Officer

Email: [***]
	  	 	904,073	 
	 Acuta Opportunity Fund, LP

1301 Shoreway Road, Suite 350

Belmont, CA 94002

Attn: Scott Smith, Chief Operating Officer

Email: [***]
	  	 	185,171	 
	 Avidity Master Fund LP

2828 N. Harwood St., Suite 1220

Dallas, TX 75201

[***]
	  	 	867,859	 

					
	 Name and Address
	  	Number of Shares of Series C
Preferred Stock Held	 
	 Avidity Capital Fund II LP

2828 N. Harwood St., Suite 1220

Dallas, TX 75201

[***]
	  	 	221,385	 
	 Strength Alliance Limited

One Broadway, 9th Floor

Cambridge, MA 02142

[***] and

[***]
	  	 	272,311	 
	 CaaS Opportunity LLC

800 Third Avenue, 26th floor

New York, New York 10022

c/o Semi Gogliormella

Email: [***]
	  	 	272,311	 
	 Novo Holdings A/S

Tuborg Havnevej 19

DK-2900 Hellerup

Denmark

Attn: Heather Ludvigsen

Email: [***]
  

with a copy (which shall not constitute notice) to:

 
 Novo Ventures (US), Inc.

501 2nd Street, Suite 300

San Francisco, CA 94107

United States

Attention: Junie Lim and Karen Hong

Email: [***] and [***]
	  	 	1,553,116	 
	 DROIA Invest II SCSP

Boulevard Joseph II 28

L-1840 Luxembourg
	  	 	1,109,368	 
	 Venrock Associates VII, L.P.

3340 Hillview Avenue

Palo Alto, CA 94304
	  	 	1,024,501	 
	 Venrock Partners VII, L.P.

3340 Hillview Avenue

Palo Alto, CA 94304
	  	 	84,867	 

					
	 Name and Address
	  	Number of Shares of Series C
Preferred Stock Held	 
	 Osage University Partners II, LP

50 Monument Rd., Suite 201

Bala Cynwyd, PA 19004
	  	 	842,342	 
	 Lightstone Ventures II, L.P.

500 Boylston Street, Suite 1380 

Boston, MA 02116
	  	 	786,265	 
	 Lightstone Ventures II (A), L.P.

500 Boylston Street, Suite 1380 

Boston, MA 02116
	  	 	45,761	 

 SCHEDULE A (cont.) 

INVESTORS 
  

					
	 Name and Address
	  	Number of Shares of
Common Stock Held	 
	 The Jackson Laboratory 

c/o Mary McWade 

Merrill Lynch 

Private Banking & Investment Group 

100 Federal Street, 17th Floor 

MA5-100-17-7
 

 Boston, MA 02110
	  	 	1,339,750	 

 SCHEDULE B 

KEY INVESTORS 
  

	
	 Key Investor Name

	 Venrock Associates VII, L.P.

	
	 Venrock Partners VII, L.P.

	
	 Celgene Corporation*

	
	 Droia Invest II SCSP

	
	 Lightstone Ventures II, L.P.

	
	 Lightstone Ventures II (A), L.P.

	
	 Osage University Partners II, LP

	
	 Novo Holdings A/S

	
	 RA Capital Healthcare Fund, L.P.

	
	 RA Capital NEXUS Fund II, L.P.

  

	*	 Celgene Corporation will constitute a “Key Investor” for purposes of the Company’s Certificate
of Incorporation for any future financing only to the extent that Celgene Corporation owns 15% or less of the outstanding shares of capital stock of the Company (on an as-converted basis, but, for clarity,
includes all shares of the Company’s common and preferred stock and excludes outstanding but unexercised stock options and shares issuable upon conversion of any other convertible securities). For the avoidance of doubt, Article Fourth, Section
B.5A.1 of the Company’s Certificate of Incorporation will apply to Celgene Corporation up until Celgene Corporation’s ownership is 15% of the outstanding shares of capital stock of the Company (on an
as-converted basis, but, for clarity, includes all shares of the Company’s common and preferred stock and excludes outstanding but unexercised stock options and shares issuable upon conversion of any
other convertible securities), even if Celgene Corporation only invests a portion of its pro rata amount in a future purchase.EX-10.3

 Exhibit 10.3 

CYTEIR THERAPEUTICS, INC. 

AMENDED AND RESTATED 2012 STOCK INCENTIVE PLAN 
  

	1.	 Purpose and Eligibility. 

The purpose of this Amended and Restated 2012 Stock Incentive Plan (the “Plan”) of Cyteir Therapeutics, Inc. (the
“Company”) is to provide stock options and other equity interests (including restricted stock, restricted stock units and other stock-based interests) in the Company (each an “Award”) to employees, officers,
directors, consultants and advisors of the Company and its Subsidiaries, all of whom are eligible to receive Awards under the Plan. Any person to whom an Award has been granted under the Plan is deemed a “Participant.” Additional
definitions are contained in Section 8. 
  

	2.	 Administration. 

a. Administration by Board of Directors. The Plan will be administered by the Board of Directors of the Company (the
“Board”). The Board, in its sole discretion, shall have the authority to grant and amend Awards, to adopt, amend and repeal rules relating to the Plan, to interpret, reconcile inconsistencies and correct the provisions of the
Plan and of any Award and, subject to the limitations of the Plan, to modify and amend any Award. All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all interested persons. Neither the
Company nor any member of the Board shall be liable for any action or determination relating to the Plan made in good faith. 
 b.
Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in
the Plan to the “Board” shall mean such Committee or the Board (or the officers referred to in Section 2(c)). 
 c.
Delegation to Executive Officers. To the extent permitted by applicable law, the Board may delegate to one or more executive officers of the Company the power to grant Awards and to exercise such other powers under the Plan as the Board may
determine, provided that the Board shall fix the maximum number of Awards to be granted and the maximum number of shares issuable to any one Participant pursuant to Awards granted by such executive officers. 

 

	3.	 Stock Available for Awards. 

a. Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the
“Common Stock”) that may be issued pursuant to Awards granted under the Plan is 23,661,918 shares. If any Award expires unexercised or is terminated, surrendered or forfeited, in whole or in part, or is settled in cash or otherwise
results in any Common Stock not being issued, the unissued Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the Plan are repurchased by, or are
surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available for the grant of Awards under the Plan. Shares of Common Stock tendered by a Participant to exercise an Award will be added to the
number of shares available for the grant of Awards. Notwithstanding the foregoing, however, the cumulative number of shares that may be issued under the Plan shall not exceed 23,661,918 shares. Shares issued under the Plan may consist in whole or in
part of authorized but unissued shares or treasury shares. 

 b. Per-Participant Limit Not Applicable.
Subject in all cases to the aggregate share limit set forth in Section 3(a), there shall be no limit on the number of shares of Common Stock that may be granted to a Participant pursuant to any Award(s) during any one fiscal year. 

c. Adjustment to Common Stock. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination or
reclassification of shares, spin-off, or other similar change in capitalization or event, (i) the number and class of securities available for Awards under the Plan and the
per-Participant share limit, (ii) the number and class of securities, vesting schedule and exercise price per share of each outstanding Award, (iii) the repurchase price per security subject to
repurchase, and (iv) the terms of each other outstanding stock-based Award shall be adjusted by the Company (or substituted Awards may be made) in a manner determined by the Board to be appropriate. If Section 7(e) applies for any event,
this Section 3(c) shall not be applicable. 
  

	4.	 Stock Options. 

a. General. The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number of
shares of Common Stock to be covered by each Option, the exercise price of each Option and the terms, conditions and limitations applicable to the grant or exercise of each Option and to the Common Stock issued upon the exercise of each Option,
including vesting provisions, repurchase provisions and restrictions upon sale or transfer thereof, as it considers advisable. 
 b.
Incentive Stock Options. An Option that the Board intends to be an “incentive stock option,” as defined in Section 422 of the Code (an “Incentive Stock Option”), shall be granted only to employees of the
Company and shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. The Board and the Company shall have no liability if an Option or any part thereof that is intended to be an Incentive Stock
Option does not qualify as such. An Option or any part thereof that does not qualify as an Incentive Stock Option is referred to herein as a “Nonstatutory Stock Option.” 

c. Exercise Price. The Board shall establish the exercise price (or determine the method by which the exercise price shall be
determined) at the time each Option is granted and specify it in the applicable Option agreement. 
 d. Vesting and Duration of
Options. Each Option shall vest and be exercisable at such times and for such periods and subject to such terms and conditions relating thereto as the Board may specify in the applicable Option agreement. 

e. Exercise of Option. Options may be exercised by delivery to the Company of a written notice of exercise signed by the proper person
together with payment in full as specified in Section 4(f) for the number of shares for which the Option is exercised. 

  
 -2- 

 f. Payment Upon Exercise. Common Stock purchased upon the exercise of an Option shall
be paid for by one or any combination of the following forms of payment: 
 (i) by check payable to the order of the Company; 

(ii) except as otherwise expressly provided in the applicable Option agreement, and only if the Common Stock is then publicly traded, delivery
of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, and any required tax withholding, or delivery by the Participant to the Company of a copy of
irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or 

(iii) to the extent permitted by applicable law but only as expressly provided in the applicable option agreement, by (x) delivery of
shares of Common Stock owned by the Participant valued at fair market value (as determined by the Board or as determined pursuant to the applicable Option agreement), (y) delivery of a promissory note of the Participant to the Company on terms
determined by the Board, or (z) payment of such other lawful consideration as the Board may determine. 
 g. Repricing of
Options. The Board may, without stockholder approval, amend any outstanding Option to reduce the exercise price of such Option. The Board may also, without stockholder approval, cancel any outstanding Option and grant in substitution therefor
new Options covering the same or a different number of shares of Common Stock and having a lower exercise price than the cancelled Option. 
  

	5.	 Restricted Stock Awards. 

a. Grants. The Board may grant Awards entitling recipients to acquire shares of Common Stock (“Restricted Stock”),
subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the Participant in the event that conditions
specified in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling recipients to receive shares of Common Stock to
be delivered in the future, with such delivery subject to a risk of forfeiture or other restrictions that will lapse upon the satisfaction of one or more conditions set forth in the applicable Award (“Restricted Stock Units”).
Restricted Stock and Restricted Stock Units are each referred to as “Restricted Stock Awards.” 
 b. Terms and
Conditions. The Board shall determine the terms and conditions of any such Restricted Stock Award. Shares of Restricted Stock shall be registered in the name of the Participant and, unless otherwise determined by the Board, shall be either
(i) held in book entry form subject to the Company’s instruction, or (ii) evidenced by a stock certificate bearing appropriate legends and deposited by the Participant, together with a stock power endorsed in blank, with the Company
(or its designee). After the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the shares of Restricted Stock no longer subject to such restrictions to the Participant or, if the Participant has died, to
the beneficiary designated by a Participant, in a manner determined by the Board, to receive amounts due or exercise rights of the Participant in the event of the Participant’s death (the “Designated Beneficiary”). In
the absence of an effective designation by a Participant, Designated Beneficiary shall mean the Participant’s estate. 

  
 -3- 

 c. Provisions Applicable to Restricted Stock Units. 

(i) Upon the vesting or lapse of restrictions with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from
the Company one share of Common Stock or, if expressly authorized by the Board in the grant of such Restricted Stock Unit, cash equal to the fair market value of one share of Common Stock. 

(ii) The Board may grant recipients of Restricted Stock Units the right to receive an amount equal to any dividends or distributions declared
and paid on an equal number of shares of Common Stock (“Dividend Equivalents”). Dividend Equivalents may be paid currently or credited to an account for the benefit of a Participant, may be settled in cash and/or shares of
Common Stock and may be subject to the same restrictions as the Restricted Stock Units in respect of which they were paid, all as set forth in the applicable Award. 

(iii) A Participant shall have no voting rights with respect to any Restricted Stock Units. 

 

	6.	 Other Stock-Based Awards. 

The Board shall have the right to grant other Awards based upon the Common Stock, or based upon any other authorized class or series of capital
stock, having such terms and conditions as the Board may determine, including, without limitation, the grant of shares based upon certain conditions, the grant of securities convertible into Common Stock and the grant of stock appreciation rights,
phantom stock awards or stock units. 
  

	7.	 General Provisions Applicable to Awards. 

a. Transferability of Awards. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned,
transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable
only by the Participant or, in the case of a Nonstatutory Stock Option, pursuant to a qualified domestic relations order. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. 

b. Documentation. Each Award under the Plan shall be evidenced by a written instrument in such form as the Board shall determine or as
executed by an officer of the Company pursuant to authority delegated by the Board. Each Award may contain terms and conditions in addition to those set forth in the Plan; provided, however, that in the event of any conflict in the terms of
the Plan and Award, the terms of the Plan shall govern. 
 c. Board Discretion. The terms of each type of Award need not be
identical, and the Board need not treat Participants uniformly. 

  
 -4- 

 d. Termination of Status. The Board shall determine the effect on an Award of the
disability, death, retirement, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative,
conservator, guardian or Designated Beneficiary, may exercise rights under the Award. 
 e. Acquisition of the Company. 

(i) Consequences of an Acquisition. Upon the consummation of an Acquisition, the Board or the board of directors of the surviving or
acquiring entity (as used in this Section 7(e)(i), also the “Board”), shall, as to outstanding Awards (on the same basis or on different bases as the Board shall specify), either: 

(A) make appropriate provision for the continuation of such Awards by the Company (if the Company is the surviving corporation)
or the assumption of such Awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such Awards either (1) the consideration payable with respect to the outstanding shares of Common
Stock in connection with the Acquisition, (2) shares of stock of the surviving or acquiring corporation, or (3) such other securities or other consideration as the Board deems appropriate, the fair market value of which (as determined by
the Board in its sole discretion) shall not materially differ from the fair market value of the shares of Common Stock subject to such Awards immediately preceding the Acquisition; or 

(B) upon written notice, provide that one or more Awards then outstanding must be exercised (to the extent vested), in whole or
in part, within a specified number of days of the date of such notice, at the end of which period such Awards shall terminate; or 

(C) provide that one or more Awards then outstanding, in whole or in part, shall be terminated in exchange for a cash payment
equal to the excess of the fair market value (as determined by the Board in its sole discretion) for the vested shares subject to such Awards over the exercise price, if any, thereof; 

Unless otherwise determined by the Board (on the same basis or on different bases as the Board shall specify), any repurchase rights or other
rights of the Company that relate to an Award shall continue to apply to consideration, including cash, that has been substituted, assumed or amended for an Award pursuant to this paragraph. The Company may require that all or any portion of any
such consideration payable in respect of an Award in connection with an Acquisition shall be held in escrow (including in an escrow pursuant to the agreement effecting such Acquisition) in order to effectuate any continuing restrictions. 

(ii) Acquisition Defined. An “Acquisition” shall mean: (x) the sale of the Company by merger or consolidation
after giving effect to which the shareholders of the Company immediately prior to such event shall, immediately following such event, hold less than a majority of the voting power of the outstanding equity securities of the Company (or its
successor); or (y) any sale, lease, exchange or other disposition of all or substantially all of the assets or capital stock of the Company (other than in a spin-off or similar transaction); or
(z) any other acquisition of the business of the Company, as determined by the Board. Notwithstanding the foregoing, a transaction shall not constitute an Acquisition if its sole purpose is to create a holding company that will be owned in
substantially the same proportions by the persons who hold the Company’s securities immediately before such transaction. 

  
 -5- 

 (iii) Assumption of Options Upon Certain Events. In connection with a merger or
consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards under the Plan in substitution for stock and stock-based awards issued by such entity or an affiliate
thereof. The substitute Awards shall be granted on such terms and conditions as the Board considers appropriate in the circumstances. 
 f.
Withholding. Each Participant shall pay to the Company, or make provisions satisfactory to the Company for payment of, any taxes required by law to be withheld in connection with Awards to such Participant no later than the date of the event
creating the tax liability. The Board may allow Participants to satisfy such tax obligations in whole or in part by transferring shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their fair
market value (as determined by the Board or as determined pursuant to the applicable option agreement). The Company may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind, including salary or wages,
otherwise due to a Participant. 
 g. Amendment of Awards. The Board may amend, modify or terminate any outstanding Award including,
but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that the
Participant’s consent to such action shall be required unless the Board determines that the action, taking into account any anticipated consequences, would not materially and adversely affect the Participant. 

h. Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) all applicable withholding obligations have been paid or provided
for, (iii) in the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or
stock market rules and regulations, and (iv) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or
regulations. 
 i. Acceleration. The Board may at any time provide that any Awards may become exercisable in full or in part or free
of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be, despite the fact that the foregoing actions may (i) cause the application of Sections 280G and 4999 of the Code if a change in control of
the Company occurs, or (ii) disqualify all or part of an Option as an Incentive Stock Option. 

  
 -6- 

 j. Compliance with Code Section 409A. No Award shall provide for
deferral of compensation that does not comply with Section 409A of the Code, unless the Board, at the time of grant or any amendment or modification, specifically provides that the Award is not intended to comply with Section 409A of the
Code. The Plan and each Award are hereby modified and limited as necessary to comply with applicable requirements of Section 409A. Notwithstanding the foregoing, neither the Company nor any member of the Board shall have any liability to a
Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A is not so exempt or compliant or for any action taken by the Board. 

 

	8.	 Miscellaneous. 

a. Definitions. 
 (i)
“Cause” means any of the following as it relates to a Participant: (i) participation in or commission of any act that would constitute a felony or a crime involving fraud, dishonesty, or moral turpitude under the laws of the
United States or any state thereof; (ii) violation of any federal or state law or regulation applicable to the Company’s business that could result in material harm to the Company or its operations; (iii) material violation of any
agreement between the Participant and the Company, any Company policy, or any statutory duty owed to the Company or its stockholders; (iv) an act of gross misconduct or of clear and material insubordination; (v) commission or attempted
commission of, or participation in, a fraud or act of dishonesty against the Company; (vi) persistent unsatisfactory performance or neglect of job duties; or (vii) any unauthorized act that results in material harm to the Company’s
business. If conduct constituting “Cause” under clause (iii) or (vi) above is reasonably susceptible of cure, Cause shall not exist unless the Participant is first given 30 days’ written notice to cure. 

(ii) “Company,” for purposes of eligibility under the Plan, shall include Cyteir Therapeutics, Inc. and any present or future
subsidiary corporations of Cyteir Therapeutics, Inc., as defined in Section 424(f) of the Code (a “Subsidiary”), and any present or future parent corporation of Cyteir Therapeutics, Inc., as defined in
Section 424(e) of the Code. For purposes of Awards other than Incentive Stock Options, the term “Company” shall include any other business venture in which the Company has a direct or indirect significant interest, as
determined by the Board in its sole discretion. 
 (iii) “Code” means the Internal Revenue Code of 1986, as amended, and
any regulations promulgated thereunder. 
 (iv) “employee” for purposes of eligibility under the Plan (but not for purposes
of Section 4(b)) shall include a person to whom an offer of employment has been extended by the Company. 
 (v) “Good
Reason” exists if any of the following occurs without a Participant’s express consent: (i) material breach of the Participant’s employment agreement by the Company; (ii) material reduction in the Participant’s
duties, position or responsibilities, taken as a whole, other than by virtue of the Company being acquired and made part of a larger entity; (iii) material reduction of the Participant’s base salary and/or bonus potential other than as
part of a similar reduction for substantially all employees or substantially all senior officers; or (iv) relocation of the Participant’s business office to another location more than fifty (50) miles away and outside the greater
Boston area, provided such relocation also materially increases the Participant’s commuting distance, and provided that no relocation will constitute Good Reason if the Participant is allowed to continue to provide services remotely (e.g.,
through telecommuting) at the time of the relocation. To resign for Good Reason, the Participant must give the Company written notice of the event or act constituting Good Reason within 60 days after its occurrence; the Company must be given 30 days
to cure such event or act; and, if the event or act is not cured by the Company, the Participant must resign within 30 days after the end of such cure period. 

  
 -7- 

 b. No Right To Employment or Other Status. No person shall have any claim or right to
be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise
terminate its relationship with a Participant free from any liability or claim under the Plan. 
 c. No Rights As Stockholder.
Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock or other capital stock to be distributed with respect to an Award until
becoming the record holder thereof. 
 d. Effective Date and Term of Plan. The Plan shall become effective on the date on which it is
adopted by the Board. No Awards shall be granted under the Plan after the completion of ten years from the date on which the Plan was adopted by the Board, but Awards previously granted may extend beyond that date. 

e. Amendment of Plan. The Board may amend, suspend or terminate the Plan or any portion thereof at any time. 

f. Authorization of Sub-Plans. The Board may establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting
supplements to this Plan containing such terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement
shall apply only to Participants within the affected jurisdiction. 
 g. Governing Law. The provisions of the Plan and all Awards
made hereunder shall be governed by, and construed and enforced in accordance, with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by, and construed and
enforced in accordance with, the internal laws of The Commonwealth of Massachusetts, without giving effect to the conflicts of laws principles thereof. 

  
 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]